Tech Session VII: Delivery to the Nervous System II
Nose-to-Brain Delivery of Novel Fingolimod-Ibuprofen Salt for Pain Relief in Multiple Sclerosis
Friday, July 18, 2025
9:38 AM - 9:49 AM EDT
Location: 119 A
Introduction: Nose-to-brain drug delivery presents a promising non-invasive alternative for directly targeting the central nervous system, bypassing the blood-brain barrier with minimal systemic side effects. Yet, the influence of particle size on nasal aerosol performance is not fully understood, rendering optimal delivery challenging (1). This study developed different sized nasally inhaled dry powder formulations containing a novel salt of fingolimod (FIN) and ibuprofen (IBU) for synergistic neuroprotection and pain management in multiple sclerosis patients, and compared their regional nasal deposition.
Learning Objectives:
At the completion of this activity, participants will know
Understand the significance of intranasal drug administration for targeting central nervous system.
Investigate the therapeutic potential of fingolimod-ibuprofen salt for multiple sclerosis treatment.
Analyze the effect of particle size on the aerosol deposition in AINI-NGI model for formulations.
Si Nga Wong, Doctor of Philosophy – Postdoc fellow, Pharmacology and Pharmacy, The University of Hong Kong & Advanced Biomedical Instrumentation Centre; Shing Fung Chow, Doctor of Philosophy – Associate Professor, Pharmacology and Pharmacy, The University of Hong Kong
